Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Usefulness of maximal oxygen pulse in timing of pulmonary valve replacement in patients with isolated pulmonary regurgitation.

Legendre A, Richard R, Pontnau F, Jais JP, Dufour M, Grenier O, Mousseaux E, Ladouceur M, Iserin L, Bonnet D.

Cardiol Young. 2016 Oct;26(7):1310-8. doi: 10.1017/S1047951115002504. Epub 2015 Dec 22.

PMID:
26692200
2.

PGE2-induced colon cancer growth is mediated by mTORC1.

Dufour M, Faes S, Dormond-Meuwly A, Demartines N, Dormond O.

Biochem Biophys Res Commun. 2014 Sep 5;451(4):587-91. doi: 10.1016/j.bbrc.2014.08.032. Epub 2014 Aug 13.

PMID:
25128827
3.

Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects.

Dufour M, Dormond-Meuwly A, Pythoud C, Demartines N, Dormond O.

Biochem Biophys Res Commun. 2013 Aug 16;438(1):32-7. doi: 10.1016/j.bbrc.2013.07.014. Epub 2013 Jul 15.

PMID:
23867821
4.

Targeting the intragraft microenvironment and the development of chronic allograft rejection.

Dormond O, Dufour M, Seto T, Bruneau S, Briscoe DM.

Hum Immunol. 2012 Dec;73(12):1261-8. doi: 10.1016/j.humimm.2012.07.334. Epub 2012 Aug 3. Review.

5.

Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.

Blaser B, Waselle L, Dormond-Meuwly A, Dufour M, Roulin D, Demartines N, Dormond O.

BMC Cancer. 2012 Mar 8;12:86. doi: 10.1186/1471-2407-12-86.

6.

Artery phantoms for intravascular optical coherence tomography: healthy arteries.

Bisaillon CÉ, Dufour ML, Lamouche G.

Biomed Opt Express. 2011 Sep 1;2(9):2599-613. doi: 10.1364/BOE.2.002599. Epub 2011 Aug 15.

7.

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.

Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O.

Mol Cancer. 2011 Jul 26;10:90. doi: 10.1186/1476-4598-10-90.

8.

The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.

Dormond-Meuwly A, Roulin D, Dufour M, Benoit M, Demartines N, Dormond O.

Biochem Biophys Res Commun. 2011 Apr 22;407(4):714-9. doi: 10.1016/j.bbrc.2011.03.086. Epub 2011 Mar 23.

PMID:
21439267
9.

Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives.

Dufour M, Dormond-Meuwly A, Demartines N, Dormond O.

Cancers (Basel). 2011 May 24;3(2):2478-500. doi: 10.3390/cancers3022478.

10.

Intravascular optical coherence tomography on a beating heart model.

Lamouche G, Dufour M, Hewko M, Vergnole S, Gauthier B, Bisaillon CE, Monchalin JP, Sowa MG.

J Biomed Opt. 2010 Jul-Aug;15(4):046023. doi: 10.1117/1.3475960.

PMID:
20799825
11.

Deformable and durable phantoms with controlled density of scatterers.

Bisaillon CE, Lamouche G, Maciejko R, Dufour M, Monchalin JP.

Phys Med Biol. 2008 Jul 7;53(13):N237-47. doi: 10.1088/0031-9155/53/13/N01. Epub 2008 Jun 17.

PMID:
18560050
12.

Circumstances of death in hospitalized patients and nurses' perceptions: French multicenter Mort-a-l'Hôpital survey.

Ferrand E, Jabre P, Vincent-Genod C, Aubry R, Badet M, Badia P, Cariou A, Ellien F, Gounant V, Gil R, Jaber S, Jay S, Paillaud E, Poulain P, Regnier B, Reignier J, Socie G, Tardy B, Lemaire F, Brun-Buisson C, Marty J; French Mort-a-l'Hôpital Group.

Arch Intern Med. 2008 Apr 28;168(8):867-75. doi: 10.1001/archinte.168.8.867.

PMID:
18443263
13.

Artifact removal in Fourier-domain optical coherence tomography with a piezoelectric fiber stretcher.

Vergnole S, Lamouche G, Dufour ML.

Opt Lett. 2008 Apr 1;33(7):732-4.

PMID:
18382533

Supplemental Content

Loading ...
Support Center